Conjugates of Tetramethylpyrazine’ metabolites and amino acid as potential antiplatelet agents
作者:Yongxi Dong、Shuxia Wu、Mingji Liu、Jiayu Huang、Yuanhu Mao、Jiquan Zhang、Zhanzhan Yang、Lei Li、Gang Liu、Shanggao Liao、Li Dong
DOI:10.1007/s00044-021-02817-3
日期:2022.1
limited its applications. 3, 5, 6-Trimethylpyrazine-2-carboxAylic acid (TMP-COOH) and 2-hydroxy-3, 5, 6-trimethylpyrazine (TMP-OH) are the two major active metabolites of TMP in vivo. Both displayed antiplatelet aggregation activity but have obvious disadvantage of rapid metabolism. In this study, conjugates of TMP-COOH/TMP-OH with amino acids were designed to address this issue. We demonstrated that 13
四甲基吡嗪(TMP)是临床常用的抗血小板药物。然而,半衰期短和生物利用度低限制了其应用。3, 5, 6-Trimethylpyrazine-2-carboxAylic acid (TMP-COOH) 和 2-hydroxy-3, 5, 6-trimethylpyrazine (TMP-OH) 是 TMP 在体内的两种主要活性代谢物。两者均具有抗血小板聚集活性,但代谢快的缺点明显。在这项研究中,设计了 TMP-COOH/TMP-OH 与氨基酸的结合物来解决这个问题。我们证明 20 种偶联物中的 13 种显示出比 TMP 更高的抗血小板聚集活性。优化后的化合物4a进一步证明可减少凝块回缩,延长出血时间、凝血酶时间、凝血酶原时间、活化部分凝血铂时间和降低纤维蛋白原含量。总之,我们证明了共轭策略可用于开发抗血小板药物的 TMP 衍生物。